SKU: R041  / 
    CAS Number: 13292-46-1

    Rifampicin Solution

    $0.00 - $125.56

    Rifampicin Solution is a sterile-filtered solution (10 mg/ml in water) that is safer than methanol or DMSO.  This aqueous formulation is easy to use: Simply add 1 ml-3 ml per liter to your culture medium.

    Rifampicin is a broad-spectrum antibiotic.   Unlike powder forms, our aqueous solution format is more convenient and unlike methanol that is used to dissolve powder formats, our Rifampicin Solution is non-toxic to plant cells.  

    We also offer:

    • Rifampicin (R003)
    • Rifampicin Sodium (R040)

    Mechanism of Action Rifampicin targets prokaryotic DNA dependent RNA polymerases which prevent subsequent RNA transcription and protein translation.
    Spectrum Rifampicin is a broad-spectrum antibiotic with a wide range of activity including: 
    • Gram-positive aerobic bacteria, particularly Staphylococcus spp and Rhodococcus equi
    • Brucella and some other fastidious organisms are susceptible but Gram-negative bacteria more generally are resistant
    • Gram-positive and Gram-negative anaerobic bacteria are inhibited at low concentrations, including Bacteroides fragilis
    • Chlamydophila and Rickettsia are susceptible
    • Mycobacterium tuberculosis: activity is high against this organism but most other mycobacteria are resistant
    • Some protozoa
    • Some fungi and poxviruses
    Microbiology Applications Rifampicin is commonly used in bacterial recombinant protein expression to inhibit bacterial RNA polymerase activity and synthesis of host bacterial proteins. Rifampicin can also be used as a selective agent to isolate Campylobacter jejuni.

    Rose et al. used Rifampicin (TOKU-E)  in methacrylate-based copolymer films and studied its effects on biofilm formation: "Prevention of biofilm formation by methacrylate-based copolymer films loaded With Rifampin, Clarithromycin, Doxycycline alone or in combination."



    Plant Biology Applications Rifampicin has been tested in Jerusalem artichoke tuber explants by adding 10 to 50 µg/ml to the tissue culture medium. At 50 µg/ml no bacterial infection was detectable, without affecting cell division rates, cytodifferentiation and DNA synthesis. As a result, Rifampicin was used as antibacterial in the following experiments of this university department (Philips, 1981).
    Eukaryotic Cell Culture Applications

    Rifampicin has been shown to have immunosuppressive effects in mice.  There are no immunosuppressive effects in humans when rifampicin is given in doses at or below clinically recommended levels.

    Rifampicin has been shown to inhibit α-synuclein fibrillation and disaggregate fibrils in a concentration-dependent manner. Rifampicin can activate pregnane X receptor (PXR), which affects cytochrome P450, and the activity of glucuronosyltransferases and P-glycoprotein. Rifampicin has been shown to enhance CYP2C-mediated metabolism, affect compounds that are transported by P-glycoprotein and metabolized by CYP3A4.

    Molecular Formula C43H58N4O12
    References

    "Rifampin: Mechanisms of Action and Resistance." Oxford Journals (1983): n. pag. Clinical Infectious Diseases. Web. 21 Aug. 2012.

    "Philips R., Arnott S.M. and K aplan S.E., 1981, Antibiotics in plant tissue culture: rifampicin effectively controls bacterial contaminants without affecting the growth of short-term explant cultures of Helianthus tuberosus. Plant Science Letters, 21 (1981) 235-240.

    Li, T., & Chiang, J. Y. (2006). Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug metabolism and disposition: the biological fate of chemicals34(5), 756-64.

    Jill E Maddison, A David J Watson, Jonathan Elliott (2008) Chapter 8 - Antibacterial drugs, Small Animal Clinical Pharmacology (Second Edition), 148-185.

    Bassi, L., Berardino, L., Arioli, V., Silvestri, L., & Lignière, E. (1973). Conditions for Immunosuppression by Rifampicin. The Journal of Infectious Diseases, 128(6), 736-744.